# Hidradenitis Suppurativa Market

> 脓疱性汗腺炎市场研究报告：按皮肤状况（粉刺、毛囊炎、深层痤疮样囊肿和黑头、脓疱）按治疗（药物和手术）以及按地区（北美、欧洲、亚太地区和世界其他地区） - 增长前景和行业预测2025至2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.72%
- **2024:** $ 0.66 Billion
- **2025:** $ 0.69 Billion
- **2035:** $ 1.1 Billion
- **Key Players:** AbbVie (US), Amgen (US), Janssen Pharmaceuticals (US), Novartis (CH), Boehringer Ingelheim (DE), Eli Lilly and Company (US), GSK (GB), Sanofi (FR), Pfizer (US) — key contributors to the expanding hidradenitis suppurativa therapeutics market landscape.

**Report ID:** MRFR/Pharma/2497-HCR · **Pages:** 68 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/hidradenitis-suppurativa-market-3770

---

## Market Summary

## **Hidradenitis Suppurativa Market Overview**

Hidradenitis Suppurativa Market Size was valued at USD 0.63 Billion in 2023. The Hidradenitis Suppurativa market industry is projected to grow from USD 0.66 Billion in 2024 to USD 0.96 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.72% during the forecast period (2024 - 2032).Increased funding for healthcare infrastructure, rising activities by public and commercial organisations to raise awareness, rising rates of obesity, and an increase in the frequency of skin diseases are all contributing factors, are the key market drivers enhancing the market growth. 

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Hidradenitis Suppurativa Market Trends**

According to forecasts made by industry insiders for the current forecast period, which will end in 2028, the market for hidradenitis suppurativa is projected to thrive with rising incidences of many skin illnesses. The FDA is approving clinical trial and drug processes, which is assisting in the growth and expansion of the worldwide hidradenitis suppurativa market.

The market is also anticipated to grow as new medicine and treatment trends are introduced, along with an increase in understanding about skin conditions and other healthcare issues. environmental changes including pollution and ozone layer depletion have been made worse by the rising degree of warming in all parts of the earth. Additionally, this is significantly affecting the target market's skin globally, which is driving the market expansion for hidradenitis suppurativa throughout the assessment period of 2017–2023.

The increasing cost of healthcare contributes to the development of the market for hidradenitis suppurativa and has a substantial impact on its growth rate. The market for hidradenitis suppurativa will also grow as a result of expanding awareness-raising campaigns by both public and private organisations and an increase in obesity incidence. Additionally, the market for hidradenitis suppurativa will grow as a result of increased disposable income and changing lifestyles of individuals. Along with this, an ageing population and an increase in smoking rates will accelerate the market's rise.

Furthermore, one of the main factors fueling market expansion (UI) is the rise in the prevalence of skin illnesses. In addition, secondary infections, hair follicle obstructions, and irritation of specific sweat glands all support the growth of the hidradenitis suppurativa market. Thus, driving the Hidradenitis Suppurativa market revenue.

## **Hidradenitis Suppurativa Market Segment Insights**

### **Hidradenitis Suppurativa Skin Conditions Insights**

The Hidradenitis Suppurativa market segmentation, based on Skin Conditions includes Pimples, Folliculitis, Deep-acne like cysts & blackheads, and Boils. The market was dominated by the deep-acne like cysts and blackheads category, which generated 29% of market revenue (0.09 billion). EGF is a very powerful [acne treatment](../../../reports/acne-treatment-market-5675), especially when used in place of harsher drugs like retinol, which also accelerate cellular turnover.

### **Hidradenitis Suppurativa Treatment Insights**

The Hidradenitis Suppurativa market segmentation, based on treatment, includes Medications and Surgery. The category of medications produced the largest revenue (68.4%). Antibiotics, biologics, retinoids, corticosteroids, and hormone therapy are among the drugs used to treat Hidradenitis Suppurativa (HS).

**Figure 1: Hidradenitis Suppurativa Market, by Treatment, 2022 & 2032 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

### **Hidradenitis Suppurativa Regional Insights**

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Hidradenitis Suppurativa Market dominated this market in 2022 (45.80%). In North America, the prevalence of HS ranges from 0.1% to 2%, with a preference for individuals in their third and fourth decades of life. The aetiology of HS is unknown, but both genetic and environmental factors are linked to the condition. The main symptom of the illness is a blockage of the hair follicles, which can result in the development of nodules, abscesses, and tunnels under the skin.

Further, the U.S. Hidradenitis Suppurativa market held the largest market share, and the Canada Armor Materials market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: HIDRADENITIS SUPPURATIVA MARKET SHARE BY REGION 2022 (USD Billion)** 

_Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_

Europe Hidradenitis Suppurativa market accounts for the second-largest market share. This is because medical therapy, which may include antibiotics, acitretin, and biologics like adalimumab and infliximab, is recommended by the European S1 guideline for the treatment of HS. Further, the German Hidradenitis Suppurativa market held the largest market share, and the UK Hidradenitis Suppurativa market was the fastest growing market in the European region

The Asia-Pacific Hidradenitis Suppurativa Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because inflammatory skin diseases are becoming more common, healthcare knowledge and government support are increasing, there are more generic manufacturers, and there are more government initiatives in this area. Moreover, China’s Hidradenitis Suppurativa market held the largest market share, and the Indian Hidradenitis Suppurativa market was the fastest growing market in the Asia-Pacific region.

**Hidradenitis Suppurativa Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Hidradenitis Suppurativa market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Hidradenitis Suppurativa industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Hidradenitis Suppurativa industry to benefit clients and increase the market sector. In recent years, the Hidradenitis Suppurativa industry has offered some of the most significant advantages to medicine. Major players in the Hidradenitis Suppurativa market, including AstraZeneca (UK), Pfizer Inc. (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US) and others, are attempting to increase market demand by investing in research and development operations.

Two German businessmen named Charles Pfizer and Charles F. Erhart founded the worldwide pharmaceutical and biotechnology company Pfizer in 1849 in New York. The business's main office is in Manhattan, New York City. Pfizer is a top biopharmaceutical firm with a strong focus on research. It uses science and resources to develop medications that help people live longer and significantly better lives. Medicines, vaccines, and many of the most well-known consumer healthcare goods are all part of the company's portfolio.

Pfizer's dedication to ESG covers a variety of areas, including product innovation, fair access to and pricing of products, product quality and safety, diversity, fairness, and inclusion, and climate change. The business has acquired a number of businesses, including Amplyx Pharmaceuticals and the fosmanogepix antifungal drug. In addition, Pfizer was fined $3 billion as a consequence of criminal convictions, civil penalties, and jury awards for engaging in dishonest marketing practises, paying off doctors, and hiding negative trial outcomes.

AstraZeneca is a multi-national, science-driven biopharmaceutical company that creates, produces, and markets drugs and biotechnology for the treatment of diseases related to oncology, the cardiovascular system, the gastrointestinal tract, and the respiratory system. Millions of patients throughout the world use the company's cutting-edge medications. The mission and values of AstraZeneca include adhering to research and prioritising patients. In addition to pioneering an oncology revolution to rethink cancer care for the millions of people living with cancer, the company has a portfolio of therapies for key diseases.

The FDA has not yet given the corporation permission to use the vaccine in an emergency situation in the US.

**Key Companies in the Hidradenitis Suppurativa market include**

### Hidradenitis Suppurativa Market Industry Developments

- **Q2 2024: UCB receives FDA approval for BIMZELX® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults** UCB announced that the U.S. Food and Drug Administration (FDA) approved BIMZELX® (bimekizumab-bkzx) for adults with moderate to severe hidradenitis suppurativa, marking a significant regulatory milestone for the company’s dermatology portfolio.
- **Q2 2024: Novartis receives European Commission approval for Cosentyx® (secukinumab) for the treatment of hidradenitis suppurativa** Novartis announced that the European Commission approved Cosentyx® (secukinumab) for the treatment of active moderate to severe hidradenitis suppurativa in adults, expanding the drug’s indications in the EU.
- **Q2 2024: AbbVie announces positive Phase 3 results for SKYRIZI® (risankizumab) in hidradenitis suppurativa** AbbVie reported that its Phase 3 clinical trial of SKYRIZI® (risankizumab) in patients with moderate to severe hidradenitis suppurativa met its primary endpoints, supporting future regulatory submissions.
- **Q1 2024: UCB submits Marketing Authorization Application to EMA for bimekizumab for hidradenitis suppurativa** UCB announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for bimekizumab for the treatment of moderate to severe hidradenitis suppurativa in adults.
- **Q3 2024: Novartis announces FDA acceptance of sBLA for Cosentyx® in hidradenitis suppurativa** Novartis announced that the U.S. FDA accepted its supplemental Biologics License Application (sBLA) for Cosentyx® (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa in adults.
- **Q2 2024: InflaRx announces positive topline results from Phase III trial of vilobelimab in hidradenitis suppurativa** InflaRx reported positive topline results from its Phase III trial evaluating vilobelimab in patients with moderate to severe hidradenitis suppurativa, supporting further regulatory discussions.
- **Q2 2024: MoonLake Immunotherapeutics announces positive Phase 2 MIRA trial results for sonelokimab in hidradenitis suppurativa** MoonLake Immunotherapeutics announced that its Phase 2 MIRA trial of sonelokimab in moderate to severe hidradenitis suppurativa met its primary and key secondary endpoints.
- **Q1 2024: InflaRx receives FDA Fast Track designation for vilobelimab in hidradenitis suppurativa** InflaRx announced that the U.S. FDA granted Fast Track designation to vilobelimab for the treatment of hidradenitis suppurativa, expediting its development and review.
- **Q2 2024: UCB launches BIMZELX® (bimekizumab) in the U.S. for hidradenitis suppurativa** Following FDA approval, UCB announced the commercial launch of BIMZELX® (bimekizumab) in the United States for adults with moderate to severe hidradenitis suppurativa.
- **Q2 2024: MoonLake Immunotherapeutics raises $400 million in public offering to advance sonelokimab for hidradenitis suppurativa** MoonLake Immunotherapeutics completed a $400 million public offering to fund the continued development and potential commercialization of sonelokimab for hidradenitis suppurativa.

## **Hidradenitis Suppurativa Market Segmentation**

### **Hidradenitis Suppurativa Skin Conditions Outlook**

### **Hidradenitis Suppurativa Treatment Outlook**

### **Hidradenitis Suppurativa Regional Outlook**

## Market Drivers

### Rising Healthcare Expenditure

医疗支出的上升趋势是引导脓疱性汗腺炎市场的重要因素。随着各国将更多资源分配给医疗保健，慢性病（如脓疱性汗腺炎）所需的长期管理和治疗受到越来越多的关注。这种财政承诺可能会增强对先进疗法的获取，并改善患者的治疗结果。报告显示，医疗支出预计每年将增长约5%，这可能转化为对皮肤病的更大投资。因此，制药公司可能会受到激励，开发和推广新的脓疱性汗腺炎治疗方案，从而扩大脓疱性汗腺炎市场。这种财政环境为患者和提供者的未来提供了良好的前景，因为管理这一挑战性疾病所需的资源将变得更加丰富。

### Advancements in Treatment Modalities

治疗方式的创新正在显著影响脓疱性汗腺炎市场。生物治疗（如阿达木单抗和英夫利西单抗）的引入改变了脓疱性汗腺炎的管理，为中重度患者带来了新的希望。这些治疗针对炎症过程中的特定通路，导致治疗结果的改善。生物制剂市场预计将大幅增长，预计未来几年复合年增长率（CAGR）将超过10%。此外，新疗法的开发，包括小分子和基因疗法，正在酝酿之中，可能进一步增强治疗选择。随着这些进展的不断出现，脓疱性汗腺炎市场可能会经历投资和研究的激增，促进更强大的治疗环境。

### Integration of Telemedicine in Dermatology

远程医疗在皮肤科实践中的整合正在成为脓疱性汗腺炎市场的一个变革性因素。远程医疗服务促进了远程咨询，使患者能够在没有地理限制的情况下获得专业护理。这对脓疱性汗腺炎患者尤其有利，因为他们可能会经历不适或行动问题。远程医疗的便利性可能会鼓励更多患者寻求治疗，从而增加市场需求。此外，使用数字平台监测和管理脓疱性汗腺炎可以增强患者的参与感和对治疗计划的遵循。随着远程医疗的持续发展，它可能会重塑皮肤科护理的格局，可能导致脓疱性汗腺炎市场中更高效和以患者为中心的方法。

### Growing Patient Advocacy and Support Groups

患者倡导和支持团体的出现在塑造脓疱性汗腺炎市场中发挥着至关重要的作用。这些组织致力于提高对脓疱性汗腺炎的认识，提供教育，并倡导更好的治疗选择。他们的努力提高了该病症的可见性，鼓励更多人寻求诊断和治疗。此外，这些团体通常与医疗专业人士和制药公司合作，促进研究和开发计划。这种倡导的存在可能会推动对创新疗法的需求，并改善患者获得护理的机会。随着社区的不断壮大，它可能会影响政策变化和资金分配，最终通过营造更支持患者的环境来使脓疱性汗腺炎市场受益。

### Increasing Prevalence of Hidradenitis Suppurativa

脓疱性汗腺炎市场（HS）患病率的上升是脓疱性汗腺炎市场的一个显著驱动因素。最近的估计表明，HS影响大约1-4%的人口，女性和20-40岁的人群的发病率更高。这种患病率的上升可能会导致对有效治疗选择的更大需求，从而扩大市场。随着意识的提高，越来越多的患者寻求医疗关注，这可能进一步促进市场的增长。对脓疱性汗腺炎患者的专业护理和管理策略的需求正变得越来越被认可，表明医疗保健的重点正在向这一病症转移。因此，脓疱性汗腺炎市场有望扩大，因为医疗服务提供者正在适应以满足这一日益增长的患者群体的需求。

## Future Outlook

脓疱性汗腺炎市场预计在2025年至2035年期间以4.72%的复合年增长率增长，推动因素包括意识的提高、创新疗法和改善的患者管理解决方案。

到2035年，脓疱性汗腺炎市场预计将实现显著增长和创新。

## Segment Insights

### 按皮肤病状：痘痘（最大）与毛囊炎（增长最快）

在脓疱性汗腺炎市场中，皮肤病状的细分涵盖了各种表现，其中痘痘是市场份额的最大贡献者，支持更广泛的脓疱性汗腺炎市场分析见解。该细分反映了大量患有脓疱性汗腺炎的患者，其中痘痘代表了一个主要的临床挑战。相比之下，[毛囊炎](https://www.marketresearchfuture.com/reports/folliculitis-market-3823)，尽管市场份额较小，但由于其在患者中日益普遍以及其在加重与脓疱性汗腺炎相关的病症中的作用而迅速获得关注。该细分的增长趋势受到意识提升和治疗选择进步的推动。皮肤科实践越来越关注毛囊炎等病症，导致患者结果改善和对特定疗法的需求增长。此外，社交媒体上围绕皮肤相关问题的讨论增加，促使患者更早寻求医疗帮助，进一步增强了痘痘和毛囊炎等主导和新兴皮肤病状的市场。

痘痘（主导）与脓疮（新兴）

痘痘仍然是脓疱性汗腺炎市场中的主导细分，因为它们的频繁发生和给患者带来的显著不适，促进了脓疱性汗腺炎市场规模的整体扩展。痘痘的特征是发炎的、充满脓液的肿块，通常与继发感染和复发相关，促使对有效治疗的需求。随着对脓疱性汗腺炎的认识增加，针对痘痘的治疗也越来越受到关注。另一方面，脓疮因其严重表现而成为一个显著的细分，如果不及时治疗可能导致并发症。尽管目前较少见，但其发生率上升引起了皮肤科医生的关注，促使针对这一病症的创新治疗方案的出现，与对痘痘管理的兴趣和资源分配相平行。

### 按治疗：药物（最大）与手术（增长最快）

在脓疱性汗腺炎市场中，治疗细分主要分为药物和手术。药物目前占据最大的市场份额，因为它们的广泛使用和在药物治疗选择中的持续发展，尤其是生物制剂和靶向疗法推动了脓疱性汗腺炎治疗市场。该细分包括系统性和局部治疗，允许满足不同患者需求的个性化管理方法。另一方面，手术干预正在获得关注，特别吸引那些对药物治疗反应不足的重症脓疱性汗腺炎患者。这种对手术解决方案日益接受的趋势表明了该市场治疗范式的转变。

手术：手术干预（主导）与药物治疗（新兴）

脓疱性汗腺炎的治疗格局正由两种主要方法塑造：手术干预和药物治疗。手术干预通常被视为对难治性疾病患者的最后手段，因其潜在的长期疾病控制和症状缓解而成为主导解决方案。这一转变推动了微创技术和个性化手术计划的创新。另一方面，药物治疗仍然相关，其特点是药物配方和给药方法的持续改进。随着新生物治疗的引入，药物治疗正作为一种务实的替代方案出现，支持脓疱性汗腺炎市场增长分析趋势。

## Regional Market Share Analysis

### North America : Leading Market for Treatments

North America is the largest market for Hidradenitis Suppurativa Market (HS), accounting for approximately 45% of the global hidradenitis suppurativa market share. The region's growth is driven by increasing awareness, advanced healthcare infrastructure, and a rising prevalence of HS, contributing to sustained hidradenitis suppurativa market growth. Regulatory support, including expedited approval processes for new therapies, further catalyzes market expansion. The U.S. is the primary contributor, with significant investments in research and development fueling innovation in treatment options. The competitive landscape in North America is robust, featuring key players such as AbbVie, Amgen, and Janssen Pharmaceuticals. These companies are actively engaged in developing novel therapies, enhancing patient access to effective treatments. The presence of established healthcare systems and a focus on patient-centric care contribute to the region's leadership in the HS market. Continuous collaboration between pharmaceutical companies and healthcare providers is expected to drive further advancements in treatment options.

### Europe : Emerging Market with Potential

Europe is an emerging powerhouse in the Hidradenitis Suppurativa Market, holding approximately 30% of the global market share and driving further hidradenitis suppurativa market analysis insights through innovation and regulatory support. The region's growth is propelled by increasing healthcare expenditure, a rising number of diagnosed cases, and supportive regulatory frameworks. Countries like Germany and France are leading the charge, with initiatives aimed at improving patient outcomes and access to innovative therapies. The European Medicines Agency (EMA) plays a crucial role in facilitating the approval of new treatments, enhancing market dynamics. Leading countries in Europe include Germany, France, and the UK, where key players such as Novartis and Boehringer Ingelheim are actively involved. The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotech firms, all striving to address the unmet needs of HS patients. Collaborative efforts between stakeholders are essential for advancing research and improving treatment protocols across the region.

### Asia-Pacific : Rapidly Evolving Market Dynamics

The Asia-Pacific region is witnessing rapid growth in the Hidradenitis Suppurativa Market, driven by increasing awareness, rising healthcare investments, and expanding adoption of advanced therapies including biologics for hs. This growth is driven by increasing awareness of HS, rising healthcare investments, and a growing patient population. Countries like Japan and Australia are at the forefront, with initiatives aimed at enhancing diagnosis and treatment options. Regulatory bodies are increasingly focusing on streamlining approval processes for new therapies, which is expected to further boost market growth. In the competitive landscape, key players such as Eli Lilly and Company and GSK are making significant strides in the region. The presence of these companies, along with local firms, is fostering innovation and improving access to treatments. As healthcare systems evolve, the focus on patient-centric care is becoming more pronounced, leading to better management of HS and improved patient outcomes across Asia-Pacific.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa (MEA) region represents an untapped market for Hidradenitis Suppurativa Market, presenting future opportunities aligned with overall hidradenitis suppurativa market growth and therapy adoption. The growth in this region is driven by increasing healthcare investments, a rising prevalence of chronic skin conditions, and a growing awareness of HS. Countries like South Africa and the UAE are beginning to implement healthcare reforms aimed at improving access to treatments and enhancing patient care. Regulatory bodies are also working towards establishing frameworks that support the introduction of new therapies. The competitive landscape in MEA is still developing, with a mix of local and international players entering the market. Companies are focusing on building partnerships with healthcare providers to improve treatment access and patient education. As the region continues to evolve, there is significant potential for growth, particularly in expanding treatment options and increasing awareness among healthcare professionals and patients alike.

## Competitive Benchmarking

The Hidradenitis Suppurativa Market is characterized by a complex competitive landscape driven by innovation, R&D investments, and advancements in biologic treatments, reinforcing broader hidradenitis suppurativa market analysis and competitive positioning.. Key players such as AbbVie (US), Amgen (US), and Janssen Pharmaceuticals (US) are actively shaping the market through innovative therapies and strategic partnerships. AbbVie (US) has positioned itself as a leader in the market with its focus on biologics, particularly the recent advancements in its pipeline targeting inflammatory skin diseases. Meanwhile, Amgen (US) emphasizes its commitment to research and development, aiming to expand its portfolio in dermatological conditions, which could enhance its competitive edge. Janssen Pharmaceuticals (US) is also notable for its strategic collaborations aimed at accelerating the development of new therapies, thereby reinforcing its market presence. The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes, which are crucial in meeting the rising demand for treatments. The Hidradenitis Suppurativa Market appears to be moderately fragmented, with several players vying for market share. However, the collective influence of these key players is significant, as they drive innovation and set industry standards, thereby shaping the overall market structure.
In August AbbVie (US) announced the initiation of a pivotal Phase 3 clinical trial for its new biologic therapy aimed at Hidradenitis Suppurativa Market. This strategic move underscores AbbVie's commitment to advancing treatment options and potentially solidifying its leadership position in the market. The trial's outcomes could significantly impact the treatment landscape, offering new hope for patients and enhancing AbbVie's competitive advantage.
In September Amgen (US) revealed a partnership with a leading research institution to explore novel therapeutic targets for Hidradenitis Suppurativa Market. This collaboration is indicative of Amgen's strategy to leverage external expertise and accelerate innovation in its product development pipeline. By aligning with academic research, Amgen may enhance its ability to bring cutting-edge therapies to market, thereby strengthening its foothold in the competitive landscape.
In October Janssen Pharmaceuticals (US) launched a new digital platform aimed at improving patient engagement and adherence to treatment regimens for Hidradenitis Suppurativa Market. This initiative reflects Janssen's recognition of the importance of digital transformation in healthcare. By enhancing patient support and education, Janssen is likely to improve treatment outcomes and foster brand loyalty, which could be pivotal in a market where patient experience is increasingly valued.
As of October the competitive trends in the Hidradenitis Suppurativa Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, it is anticipated that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This transition may ultimately enhance patient care and reshape the market dynamics.

## Recent News & Developments

- **Q2 2024: UCB receives FDA approval for BIMZELX® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa in adults** UCB announced that the U.S. Food and Drug Administration (FDA) approved BIMZELX® (bimekizumab-bkzx) for adults with moderate to severe hidradenitis suppurativa, marking a significant regulatory milestone for the company’s dermatology portfolio.
- **Q2 2024: Novartis receives European Commission approval for Cosentyx® (secukinumab) for the treatment of hidradenitis suppurativa** Novartis announced that the European Commission approved Cosentyx® (secukinumab) for the treatment of active moderate to severe hidradenitis suppurativa in adults, expanding the drug’s indications in the EU.
- **Q2 2024: AbbVie announces positive Phase 3 results for SKYRIZI® (risankizumab) in hidradenitis suppurativa** AbbVie reported that its Phase 3 clinical trial of SKYRIZI® (risankizumab) in patients with moderate to severe hidradenitis suppurativa met its primary endpoints, supporting future regulatory submissions.
- **Q1 2024: UCB submits Marketing Authorization Application to EMA for bimekizumab for hidradenitis suppurativa** UCB announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for bimekizumab for the treatment of moderate to severe hidradenitis suppurativa in adults.
- **Q3 2024: Novartis announces FDA acceptance of sBLA for Cosentyx® in hidradenitis suppurativa** Novartis announced that the U.S. FDA accepted its supplemental Biologics License Application (sBLA) for Cosentyx® (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa in adults.
- **Q2 2024: InflaRx announces positive topline results from Phase III trial of vilobelimab in hidradenitis suppurativa** InflaRx reported positive topline results from its Phase III trial evaluating vilobelimab in patients with moderate to severe hidradenitis suppurativa, supporting further regulatory discussions.
- **Q2 2024: MoonLake Immunotherapeutics announces positive Phase 2 MIRA trial results for sonelokimab in hidradenitis suppurativa** MoonLake Immunotherapeutics announced that its Phase 2 MIRA trial of sonelokimab in moderate to severe hidradenitis suppurativa met its primary and key secondary endpoints.
- **Q1 2024: InflaRx receives FDA Fast Track designation for vilobelimab in hidradenitis suppurativa** InflaRx announced that the U.S. FDA granted Fast Track designation to vilobelimab for the treatment of hidradenitis suppurativa, expediting its development and review.
- **Q2 2024: UCB launches BIMZELX® (bimekizumab) in the U.S. for hidradenitis suppurativa** Following FDA approval, UCB announced the commercial launch of BIMZELX® (bimekizumab) in the United States for adults with moderate to severe hidradenitis suppurativa.
- **Q2 2024: MoonLake Immunotherapeutics raises $400 million in public offering to advance sonelokimab for hidradenitis suppurativa** MoonLake Immunotherapeutics completed a $400 million public offering to fund the continued development and potential commercialization of sonelokimab for hidradenitis suppurativa.

## Report Scope

| MARKET SIZE 2024 | 0.66(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.6912(USD Billion) |
| MARKET SIZE 2035 | 1.096(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.72% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | AbbVie (US), Amgen (US), Janssen Pharmaceuticals (US), Novartis (CH), Boehringer Ingelheim (DE), Eli Lilly and Company (US), GSK (GB), Sanofi (FR), Pfizer (US) |
| Segments Covered | Skin Conditions, Treatment, Region |
| Key Market Opportunities | Advancements in biologic therapies enhance treatment options in the Hidradenitis Suppurativa Market. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the Hidradenitis Suppurativa market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for Hidradenitis Suppurativa in 2035?**
A: The projected market valuation for Hidradenitis Suppurativa in 2035 is 1.096 USD Billion.

**Q: What was the market valuation for Hidradenitis Suppurativa in 2024?**
A: The overall market valuation for Hidradenitis Suppurativa was 0.66 USD Billion in 2024.

**Q: What is the expected CAGR for the Hidradenitis Suppurativa Market from 2025 to 2035?**
A: The expected CAGR for the Hidradenitis Suppurativa Market during the forecast period 2025 - 2035 is 4.72%.

**Q: Which companies are the key players in the Hidradenitis Suppurativa Market?**
A: Key players in the Hidradenitis Suppurativa Market include AbbVie, Amgen, Janssen Pharmaceuticals, Novartis, Boehringer Ingelheim, Eli Lilly and Company, GSK, Sanofi, and Pfizer.

**Q: What are the main segments of the Hidradenitis Suppurativa Market?**
A: The main segments of the Hidradenitis Suppurativa Market include Skin Conditions and Treatment.

**Q: What was the market size for medications in the Hidradenitis Suppurativa Market in 2024?**
A: In 2024, the market size for medications in the Hidradenitis Suppurativa Market was 0.396 USD Billion.

**Q: What is the projected market size for surgeries in the Hidradenitis Suppurativa Market by 2035?**
A: The projected market size for surgeries in the Hidradenitis Suppurativa Market by 2035 is expected to reach 0.462 USD Billion.

**Q: How much did the segment for boils contribute to the Hidradenitis Suppurativa Market in 2024?**
A: The segment for boils contributed 0.29 USD Billion to the Hidradenitis Suppurativa Market in 2024.

**Q: What is the anticipated growth for the deep-acne like cysts and blackheads segment by 2035?**
A: The anticipated growth for the deep-acne like cysts and blackheads segment is projected to reach 0.2 USD Billion by 2035.

**Q: How does the market for folliculitis compare to other skin conditions in 2024?**
A: In 2024, the market for folliculitis was valued at 0.1 USD Billion, indicating a smaller contribution compared to other skin conditions.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hidradenitis-suppurativa-market-3770*